Discover and read the best of Twitter Threads about #CTAD22
Most recents (5)
Right now, we're going after the pathology of the disease–plaques & tangles-but I think we need to start going after the biology and, as a result, the pharmacology that addresses the altered biology with aging that occurs in Alzheimer's-@a_hfillit @TheADDF
biospace.com/article/ctad-2…
biospace.com/article/ctad-2…
“Lecanemab slows #cognitivedecline. But this is only a start to stopping Alzheimer’s in its tracks. We have a lot of ground to cover to get from the 27% slowing #lecanemab offers to our goal of slowing cognitive decline by 100%"-@a_hfillit on #CTAD22 data
alzdiscovery.org/news-room/anno…
alzdiscovery.org/news-room/anno…
“The mixed data shows that while anti-amyloids are a promising starting point, we will need a combination of drugs aimed at different targets informed by the biology of aging to effectively treat this disease”
-@a_hfillit, M.D., co-founder and CSO @TheADDF
fiercebiotech.com/biotech/roche-…
-@a_hfillit, M.D., co-founder and CSO @TheADDF
fiercebiotech.com/biotech/roche-…
After 18 months, participants who received lecanemab scored, on average, 0.45 points better on the CDR-SB than those who got a placebo. Some researchers, however, have questioned whether this shift is big enough to make a noticeable difference in a person’s symptoms @meprillaman
It’s a modest benefit, says @BrentForester, director of the Geriatric Psychiatry Research Program @McLeanHospital who helped to run the clinical trial for lecanemab. His concerns lie with safety. About 20% of treated people had brain-scan anomalies
#CTAD22
#CTAD22
If a connection between lecanemab and the deaths is found, it could pose “a real conundrum” for the US Food and Drug Administration as it decides how to rule on lecanemab, says Caleb Alexander @JohnsHopkinsSPH and an advisory committee member for the FDA
nature.com/articles/d4158…
nature.com/articles/d4158…
ANAVEX®2-73-AD-004 was a randomized, double-blind, multicenter, placebo-controlled 509 patient Phase 2b/3 study (randomized 1:1:1 to mid or high dose of ANAVEX®2-73 or placebo), for the treatment of early Alzheimer’s disease over 48 weeks @AnavexLifeSci
anavex.com/post/anavex-2-…
anavex.com/post/anavex-2-…
We are very pleased to see such positive clinical data in patients with Alzheimer’s, thereby emphasizing the potentially significant implications these findings have for patients, caregivers & healthcare systems worldwide
-Edward Hammond CMO @AnavexLifeSci
finance.yahoo.com/news/anavex-2-…
-Edward Hammond CMO @AnavexLifeSci
finance.yahoo.com/news/anavex-2-…
These clinical study findings confirm the robustness of the @AnavexLifeSci precision medicine platform, and we look forward to advancing ANAVEX®2-73 as a potential new treatment option for Alzheimer’s
-Christopher Missling CEO $AVXL
anavex.com/post/anavex-2-…
-Christopher Missling CEO $AVXL
anavex.com/post/anavex-2-…
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points: 
1) This trial is much better than the frustrating data associated with Aducanumab. Demographics are well balanced between groups and are (somewhat) more representative, the protocol is coherent and there aren’t major technical problems.
The drug clearly engaged its target, massively lowering β-amyloid levels in the first year of treatment based on amyloid PET scans.
Today’s exciting #lecanemab results offer our best hope yet for not only delaying symptom progression for people with early stage Alzheimer’s, but, significantly, slowing the loss of quality of life for them and their carers. @RichJamesOakley explains from #CTAD22.
He added we were pleased to see a recommitment to the National Dementia Mission on Monday but said this crucial doubling of dementia research funding must be delivered urgently to boost research for all types of dementia so no one is forgotten.
Thank you for all of the interest in these exciting drug developments. Please bear with us while we work through your questions; our research team are in San Francisco at the Clinical Trials in Alzheimer’s Disease conference. More info on lecanemab here: alzheimers.org.uk/blog/three-pro…
